Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
Public ClinicalTrials.gov record NCT01259726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of this study are: (1) to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days in adults previously treated for CDI; (2) to characterize the frequency and duration of stool colonization with the VP 20621 strain of C. difficile; (3) to evaluate the efficacy of VP 20621 for prevention of recurrence of CDI; and (4)to select a dose regimen of VP 20621 to be used in future studies.
Study identification
- NCT ID
- NCT01259726
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 173 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2011 (Actual)
- Primary completion
- Jun 11, 2013 (Actual)
- Completion
- Jun 11, 2013 (Actual)
- Last update posted
- Jun 10, 2021
2011 – 2013
United States locations
- U.S. sites
- 42
- U.S. states
- 24
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Modesto | California | — | — |
| Not listed | Palm Desert | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Hartford | Connecticut | — | — |
| Not listed | Bay Pines | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Maywood | Illinois | — | — |
| Not listed | Anderson | Indiana | — | — |
| Not listed | Lafayette | Indiana | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Chevy Chase | Maryland | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Grosse Pointe Woods | Michigan | — | — |
| Not listed | Novi | Michigan | — | — |
| Not listed | Royal Oak | Michigan | — | — |
| Not listed | Sault Ste. Marie | Michigan | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Butte | Montana | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | North Massapequa | New York | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Lima | Ohio | — | — |
| Not listed | Toledo | Ohio | — | — |
| Not listed | Lancaster | Pennsylvania | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Temple | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Winchester | Virginia | — | — |
| Not listed | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01259726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01259726 live on ClinicalTrials.gov.